COMMUNIQUÉS West-GlobeNewswire

Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
05/08/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of [...]
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
05/08/2026
BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
05/08/2026
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral [...]
AC Immune First Half 2026 Financial and Corporate Update
05/08/2026
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, [...]
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
05/08/2026
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
05/08/2026
-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference Call Today at 8: [...]
Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada
05/08/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced the market launch of neffy ® 2 mg in Canada following the approval by Health Canada in April 2026. The launch of this first ever nasal adrenaline spray for [...]
Applied Biologics Receives Central IRB Approval for Phase 3 BIOxHEAL™ Clinical Trial
05/08/2026
Clinical site activation and patient enrollment expected to begin in the coming weeks SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic [...]
Kane Biotech Announces Engagement of DNA Advisors
05/08/2026
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company [...]
Bioventus Reports Second Quarter Financial Results
05/08/2026
Q2 reported revenue of $153.2 million increased 4% Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share Non-GAAP earnings* of $0.22 per diluted share compared [...]
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
05/08/2026
WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies [...]
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
05/08/2026
- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 - - Phase 3 [...]
Medline Reports Second Quarter and First Six Months 2026 Results
05/08/2026
Second quarter net sales of $7.7 billion, an increase of 11.6% Second quarter net income of $139 million, a decrease of 58.3% Second quarter Adjusted EBITDA 1 of $1.1 billion, an increase of 13.4% First six months net [...]
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
05/08/2026
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell’s next generation personalized immunotherapy for [...]
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
05/08/2026
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that [...]
Kura Oncology to Report Second Quarter Financial Results
05/08/2026
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will [...]
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
05/08/2026
Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future value KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc [...]
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
05/08/2026
-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 [...]
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
05/08/2026
ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and UGN- [...]

Pages